Sebetralstat is a small molecule commercialized by Kalvista Pharmaceuticals, with a leading Phase III program in Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency). According to Globaldata, it is involved in 6 clinical trials, of which 3 were completed, and 3 are ongoing. GlobalData uses proprietary data and analytics to provide a complete picture of Sebetralstat’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
The revenue for Sebetralstat is expected to reach an annual total of $169 mn by 2033 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
Sebetralstat (KVD-900) is under development for the treatment of hereditary angioedema. The drug candidate is administered through the oral route in the form of the tablet. It acts by targeting plasma kallikrein.
Kalvista Pharmaceuticals Overview
Kalvista Pharmaceuticals (Kalvista) is a Biotech company. It focusses on the discovery, development, and commercialization of small molecule protease inhibitors. Its products include KVD824 and KVD001, a plasma kallikrein inhibitor that is in Phase II clinical trials for the treatment of DME; and KVD900, a potent inhibitor of plasma kallikrein, which is in Phase I clinical trial for treating HAE. The company’s product candidates are inhibitors of plasma kallikrein, which is being developed for hereditary angioedema (HAE) and diabetic macular edema (DME) indications. Kalvista is also progressing additional oral candidates towards regulatory preclinical studies. The company has its operations in the US and the UK. Kalvista is headquartered in Cambridge, Massachusetts, the US.
The operating loss of the company was US$96.6 million in FY2022, compared to an operating loss of US$57.9 million in FY2021. The net loss of the company was US$82.3 million in FY2022, compared to a net loss of US$46.2 million in FY2021.
For a complete picture of Sebetralstat’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.